Baker Hughes (BKR.US) has submitted remedies to the European Union in order to seek antitrust approval for its acquisition of Chart Industries, Inc. (GTLS.US).
U.S. oilfield services giant Baker Hughes has submitted a remedy plan to EU regulatory authorities in an effort to clear antitrust hurdles for its $13.6 billion acquisition of Chart Industries.
American oilfield service giant Baker Hughes (BKR.US) has submitted a remedy proposal to EU regulators in hopes of clearing antitrust barriers for its $13.6 billion acquisition of Chart Industries, Inc. (Chart Industries, GTLS.US). Documents revealed by the European Commission on Monday confirmed the progress of the above.
As the EU competition enforcement agency, the European Commission did not disclose the specific content of the remedies as usual, but set a deadline of July 10 for the final decision. It is reported that the Commission will decide whether to accept the proposal, request further supplements, or initiate a four-month in-depth investigation in case of significant concerns after collecting feedback from customers and competitors of both parties.
Baker Hughes announced this acquisition in July last year, aiming to strengthen its industrial technology services capabilities in the liquefied natural gas (LNG) and data center sectors, as well as integrating the industrial and energy technology portfolios of both sides. Chart Industries, Inc. mainly operates industrial equipment such as valves and gas/liquid molecular processing measurement devices, with 65 production sites and over 50 service centers globally.
Related Articles

US Stock Market Move | AbbVie, Inc. (ABBV.US) rises 6% to acquire Apogee for $10.9 billion.

US Stock Market Move | Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose by 6% as Semaglutide's market exclusivity in China is extended.

Weak demand combined with operational pressures: Lucid (LCID.US) announced a 18% reduction in its US workforce and the elimination of the COO position.
US Stock Market Move | AbbVie, Inc. (ABBV.US) rises 6% to acquire Apogee for $10.9 billion.

US Stock Market Move | Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose by 6% as Semaglutide's market exclusivity in China is extended.

Weak demand combined with operational pressures: Lucid (LCID.US) announced a 18% reduction in its US workforce and the elimination of the COO position.

RECOMMEND





